Note 1 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended		9 Months Ended
	Apr. 19, 2023	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Number of Tumor Samples		150,000		150,000
Number of Operating Segments				3
Retained Earnings (Accumulated Deficit)		$ 164,286,536		$ 164,286,536		$ 153,777,916
Cash and Cash Equivalents, at Carrying Value		11,915,048		11,915,048		22,071,523
Liabilities, Current		4,171,891		4,171,891		3,882,670
Accounts Payable and Accrued Liabilities, Current		2,979,064		2,979,064
Operating Lease, Liability, Current		555,541		555,541		94,237
Notes Payable, Current		$ 260,220		$ 260,220		0
Short-Term Debt, Percentage Bearing Fixed Interest Rate		9.25%		9.25%
Operating Lease, Liability, Noncurrent		$ 2,343,622		$ 2,343,622		86,082
Operating Lease, Weighted Average Remaining Lease Term (Year)		4 years 2 months 23 days		4 years 2 months 23 days
Net Cash Provided by (Used in) Operating Activities				$ 10,107,030	$ 9,135,812
Accounts Receivable, Allowance for Credit Loss, Current		$ 0		0		0
Accounts Receivable, after Allowance for Credit Loss		544,756		544,756		331,196	$ 354,196
Contract with Customer, Liability		374,957		374,957		$ 602,073	$ 186,951
Contract liabilities				(227,116)	(64,889)
Research and Development Expense		20,671	$ 15,150	88,843	$ 116,763
Income Tax Expense (Benefit)				0
Unrecognized Tax Benefits		0		0
Cash, Uninsured Amount		$ 34,853		$ 34,853
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20